

Hikma Pharmaceuticals PLC

Results of 2026 Annual General Meeting

LONDON, 23 April 2026 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the ‘Company’ or ‘Hikma’) announces that its Annual General Meeting (‘AGM’) was held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN earlier today (23 April 2026) and commenced at 11.00 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 (inclusive) were passed as ordinary resolutions and Resolutions 17 to 20 (inclusive) were passed as special resolutions. Resolutions 21 to 22 (inclusive) were passed as ordinary resolutions on which only Independent Shareholders (that is, excluding members of the Concert Party, in accordance with the City Code on Takeovers and Mergers) were entitled to vote.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA’s Electronic Submission System and will be available from the National Storage Mechanism. Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Notice of Meeting dated 18 March 2026.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the Notice of Meeting dated 18 March 2026) is set out below. The number of Ordinary Shares in issue at the close of business on 21 April 2026 was 230,345,591. At that time there were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 217,512,358.

Resolution	Votes For	% of Eligible Votes	Votes Against	% of Eligible Votes	Total Votes Cast	Total votes cast as a % of ISC ¹	Withheld ²
1. To receive the 2025 report and accounts	163,275,312	99.99%	17,475	0.01%	163,292,787	75.07%	1,019,017
2. To approve a final dividend of 48 cents per share	164,299,386	99.99%	6,064	0.01%	164,305,450	75.54%	6,354
3. To re-appoint PricewaterhouseCoopers LLP as Auditor	163,553,679	99.57%	705,615	0.43%	164,259,294	75.52%	52,510
4. To authorise the Audit Committee to determine the remuneration of the Auditor	164,274,950	99.99%	23,884	0.01%	164,298,834	75.54%	12,970
5. To elect Khalid Nabils as a Director	162,775,703	99.08%	1,514,619	0.92%	164,290,322	75.53%	21,482
6. To re-elect Victoria Hull as a Director	161,115,526	98.09%	3,135,584	1.91%	164,251,110	75.51%	60,694
7. To re-elect Said Darwazah as a Director	162,778,631	99.08%	1,511,493	0.92%	164,290,124	75.53%	21,680
8. To re-elect Mazen Darwazah as a Director	160,180,915	97.50%	4,107,459	2.50%	164,288,374	75.53%	23,430
9. To re-elect Douglas Hurt as a Director	163,661,379	99.64%	591,090	0.36%	164,252,469	75.51%	59,335
10. To re-elect Ali Al-Husry as a Director	162,593,736	98.99%	1,657,276	1.01%	164,251,012	75.51%	60,792
11. To re-elect Cynthia Flowers as a Director	164,036,930	99.87%	214,050	0.13%	164,250,980	75.51%	60,824

Resolution	Votes For	% of Eligible Votes	Votes Against	% of Eligible Votes	Total Votes Cast	Total votes cast as a % of ISC ¹	Withheld ²
12. To re-elect Laura Balan as a Director	164,087,521	99.90%	167,257	0.10%	164,254,778	75.52%	57,026
13. To re-elect Dr Deneen Vojta as a Director	163,468,063	99.88%	201,369	0.12%	163,669,432	75.25%	642,372
14. To receive and approve the annual report on remuneration	159,288,908	96.98%	4,961,703	3.02%	164,250,611	75.51%	61,193
15. To approve the Directors' Remuneration Policy	162,548,305	98.96%	1,700,931	1.04%	164,249,236	75.51%	62,568
16. To authorise the Directors to allot shares and grant rights to subscribe for shares	161,666,855	98.40%	2,622,154	1.60%	164,289,009	75.53%	22,795
17. To authorise the disapplication of pre-emption rights (General)	159,554,398	97.12%	4,735,766	2.88%	164,290,164	75.53%	21,640
18. To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment)	149,676,154	91.10%	14,614,113	8.90%	164,290,267	75.53%	21,537
19. To authorise the Company to purchase its own Ordinary Shares	164,030,277	99.96%	64,165	0.04%	164,094,442	75.44%	217,362
20. To authorise the Company to hold general meetings on not less than 14 clear days' notice	161,251,197	98.14%	3,053,144	1.86%	164,304,341	75.54%	7,463
21. To approve the Rule 9 Waiver (Buyback Waiver) ³	92,574,383	91.26%	8,869,249	8.74%	101,443,632	46.64%	2,868,172
22. To approve the Rule 9 Waiver (2027 Awards Waiver) ³	97,017,031	95.65%	4,416,329	4.35%	101,433,360	46.63%	2,878,444

¹ Issued Ordinary Share capital of the Company (excluding treasury shares) at the close of business on 21 April 2026.

² A "withheld" vote is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

³ In order to comply with the City Code on Takeovers and Mergers, only the votes cast by independent shareholders were counted for the purposes of Resolutions 21 to 22.

Declaration of final dividend

The dividend of 48 cents per share will be paid on 30 April 2026 to shareholders on the register at the close of business on 20 March 2026. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.36 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa \$1 to 0.708JD.

Approval of Rule 9 Waiver

The number of Ordinary Shares in which the Concert Party was collectively interested in at the close of business on 21 April 2026 was 65,146,443, representing approximately 29.95% of the Ordinary Shares carrying voting rights in the capital of the Company.

The combined effect of the Buyback Waiver, the 2027 Awards Waiver and the Company's pre-existing Rule 9 waivers as approved by shareholders at the 2024 AGM and the 2025 AGM would allow the Concert Party's interest in Ordinary Shares as a proportion of the Company's total share capital to increase, but only to the extent that the resulting interest of the Concert Party would not exceed 33.99% of the issued and voting share capital of the Company.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Helen Middlemist
Group Company Secretary

+44 20 7399 2670